| Not Yet Recruiting | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event NCT07499128 | National Cancer Institute (NCI) | N/A |
| Not Yet Recruiting | Investigating Real-Time Immunotherapy Symptoms Study NCT07280715 | University of Pittsburgh | N/A |
| Recruiting | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer NCT06768931 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing L NCT07461675 | University of Geneva, Switzerland | Phase 3 |
| Recruiting | Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Ca NCT07475403 | Tianjin Medical University Second Hospital | Phase 2 |
| Not Yet Recruiting | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer NCT07369986 | Women's Hospital School Of Medicine Zhejiang University | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer NCT07409844 | Ismail Gögenur | Phase 2 |
| Not Yet Recruiting | Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02) NCT07396116 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | N/A |
| Not Yet Recruiting | A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined Wit NCT07113275 | Tao Zhang | Phase 3 |
| Recruiting | Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal NCT07458529 | Seventh Medical Center of PLA General Hospital | Phase 2 |
| Not Yet Recruiting | IMMUNO-FIT Observational Study NCT07354971 | University Hospital Southampton NHS Foundation Trust | — |
| Not Yet Recruiting | Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer NCT05909137 | Xinqiao Hospital of Chongqing | — |
| Not Yet Recruiting | Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma NCT07259473 | Shanghai Zhongshan Hospital | Phase 2 |
| Not Yet Recruiting | Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Inst NCT07266025 | Shanghai Zhongshan Hospital | Phase 2 |
| Not Yet Recruiting | A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Adva NCT07271602 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Not Yet Recruiting | Exercise as a Tool to Improve Response to Immunotherapy in Non-small Cell Lung Cancer NCT07267000 | Medical University of Graz | N/A |
| Withdrawn | Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients NCT04329221 | Massachusetts General Hospital | Phase 2 |
| Not Yet Recruiting | A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed b NCT07239466 | Tao Zhang | Phase 2 |
| Withdrawn | Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients NCT04642287 | Massachusetts General Hospital | Phase 2 |
| Not Yet Recruiting | A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients Wit NCT07269158 | Yonsei University | Phase 1 / Phase 2 |
| Recruiting | Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer NCT07261683 | Obstetrics & Gynecology Hospital of Fudan University | Phase 2 |
| Recruiting | Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing He NCT07436845 | Nanfang Hospital, Southern Medical University | — |
| Not Yet Recruiting | Effect of G-CSF on MDSC and Cancer Stem-cells Interactions in Non-small Cell Lung Cancers (CIRCUIT) NCT06711770 | University Hospital, Bordeaux | N/A |
| Recruiting | Jack Jumper Ant Venom Immunotherapy Long-term Effectiveness Investigation NCT06935890 | Murdoch Childrens Research Institute | Phase 4 |
| Recruiting | A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC NCT07244705 | Anbogen Therapeutics, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. NCT07110662 | Hospices Civils de Lyon | Phase 1 / Phase 2 |
| Recruiting | Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Can NCT06671613 | VA Office of Research and Development | N/A |
| Recruiting | Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced NCT07289997 | Hebei Medical University Fourth Hospital | Phase 2 |
| Not Yet Recruiting | Lymphocyte Function Testing in Immuno-oncology NCT07155811 | Centre Leon Berard | N/A |
| Recruiting | VSV-02 Compassionate Use in Advanced Solid Tumors NCT07260591 | The First Affiliated Hospital of Xinxiang Medical College | Phase 1 |
| Not Yet Recruiting | Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multip NCT07191405 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Not Yet Recruiting | Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment NCT07168668 | Chang Gung Memorial Hospital | Phase 2 |
| Recruiting | Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Ju NCT07072351 | West China Hospital | Phase 1 / Phase 2 |
| Recruiting | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC NCT07198165 | Ruijin Hospital | Phase 2 |
| Not Yet Recruiting | A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With NCT07128251 | Anhui Provincial Hospital | Phase 2 |
| Not Yet Recruiting | Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignan NCT07118566 | China Medical University, China | Phase 2 |
| Not Yet Recruiting | A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injec NCT07131501 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Not Yet Recruiting | A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC NCT07086326 | Yang Fan, MD | Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of NCT07070713 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC NCT07085234 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligomet NCT07062055 | Shandong Cancer Hospital and Institute | Phase 2 |
| Recruiting | Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and NCT07165847 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Recruiting | Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) NCT05690048 | Michael Dill | Phase 2 |
| Active Not Recruiting | Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer NCT07359040 | Peking University People's Hospital | — |
| Recruiting | The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Tri NCT07212933 | Chinese PLA General Hospital | Phase 2 |
| Recruiting | A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Al NCT07040956 | West China Hospital | Phase 2 |
| Not Yet Recruiting | Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer NCT06848439 | Jiangsu Cancer Institute & Hospital | Phase 2 |
| Recruiting | Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. NCT06903312 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 4 |
| Recruiting | A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resect NCT07010120 | West China Hospital | Phase 1 / Phase 2 |
| Enrolling By Invitation | Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain NCT07088081 | Ain Shams University | — |
| Recruiting | Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy NCT06985485 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Recruiting | To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigen NCT07291921 | Peking University People's Hospital | — |
| Recruiting | Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer NCT07166003 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Recruiting | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies NCT07327489 | Elephas | — |
| Not Yet Recruiting | Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and NCT06896552 | Rabin Medical Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patie NCT06797479 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanc NCT06521866 | Fudan University | Phase 2 |
| Recruiting | Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on NCT07396259 | Chang Gung Memorial Hospital | — |
| Recruiting | Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients NCT06915389 | Qinghai Red Cross Hospital | — |
| Recruiting | Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS) NCT06717243 | Oncology Center of Biochemical Education And Research | — |
| Recruiting | The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the NCT06738160 | Fudan University | Phase 2 |
| Recruiting | A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors NCT06716619 | Guangzhou FineImmune Biotechnology Co., LTD. | Phase 1 |
| Recruiting | CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC NCT06964568 | Fudan University | Phase 3 |
| Not Yet Recruiting | Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study NCT06743555 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 1 |
| Not Yet Recruiting | Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherap NCT06768307 | Peking University Cancer Hospital & Institute | Phase 2 |
| Not Yet Recruiting | Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer NCT06743581 | Centre hospitalier de l'Université de Montréal (CHUM) | N/A |
| Recruiting | Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy C NCT06849193 | Zhongda Hospital | — |
| Not Yet Recruiting | A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma NCT06781112 | Weiwei Zhang | Phase 2 |
| Recruiting | Probiotics in Advanced Urothelial Carcinoma NCT06904573 | Sun Yat-sen University | Phase 2 |
| Recruiting | The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating L NCT07069842 | Changzhi People's Hospital Affiliated to Changzhi Medical College | — |
| Recruiting | Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy NCT06764680 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma NCT06755567 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Not Yet Recruiting | Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions NCT06649838 | Peking Union Medical College Hospital | — |
| Recruiting | A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted NCT06741982 | West China Hospital | Phase 1 |
| Active Not Recruiting | Optimal Combination of Adjuvant Radiotherapy and Immunotherapy for Breast Cancer NCT07046195 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer NCT06946745 | jianming xu | — |
| Recruiting | Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunot NCT06734702 | Sun Yat-sen University | Phase 3 |
| Recruiting | Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study NCT07020247 | West China Hospital | Phase 3 |
| Recruiting | SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carci NCT06676722 | The First Affiliated Hospital of Xiamen University | Phase 2 |
| Recruiting | Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases NCT06702826 | Rongrong Zhou | Phase 2 |
| Recruiting | Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor NCT06826079 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 / Phase 3 |
| Recruiting | TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC NCT06676449 | Fudan University | Phase 3 |
| Not Yet Recruiting | Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Ca NCT06600841 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma NCT06542796 | Second Affiliated Hospital, School of Medicine, Zhejiang University | N/A |
| Active Not Recruiting | Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Can NCT07230080 | Nanfang Hospital, Southern Medical University | — |
| Not Yet Recruiting | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma NCT06567600 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Not Yet Recruiting | Rehabilitation Needs for Hematologic Cancer Candidate for Hematopoietic Stem Cell Transplantation or CAR T-Cel NCT06506396 | University of Modena and Reggio Emilia | — |
| Not Yet Recruiting | Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitor NCT06523049 | Hao Zeng | Phase 2 |
| Not Yet Recruiting | Investigating The Experiences of Patients In Immunotherapy Clinical Trials NCT05435365 | Power Life Sciences Inc. | — |
| Recruiting | Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immu NCT06461780 | Taipei Veterans General Hospital, Taiwan | N/A |
| Not Yet Recruiting | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cispla NCT06490198 | Chang Gung Memorial Hospital | Phase 1 |
| Recruiting | 68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer. NCT06608160 | Ruijin Hospital | — |
| Recruiting | Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma NCT06413342 | Zhejiang Cancer Hospital | Phase 2 |
| Recruiting | Nutrition Impact on Immunotherapy of Cancer NCT06500234 | Qingdao Central Hospital | Phase 3 |
| Recruiting | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK NCT05266846 | Hunan Province Tumor Hospital | Phase 2 |
| Recruiting | bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma NCT06070636 | Sun Yat-sen University | N/A |
| Recruiting | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC NCT06061276 | Sun Yat-sen University | N/A |
| Recruiting | A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Ma NCT06635954 | Oxford Biodynamics Inc. | — |
| Recruiting | Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer NCT06421376 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC NCT06573424 | fan li | — |
| Recruiting | Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced NCT06510660 | Fujian Medical University Union Hospital | Phase 2 |
| Recruiting | Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver NCT06356584 | Shandong Cancer Hospital and Institute | Phase 2 |
| Recruiting | Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemot NCT06037733 | Hubei Cancer Hospital | N/A |
| Recruiting | De-escalated Radiotherapy for Primary Tumor After Neoadjuvant Therapy With Toripalimab Plus Chemotherapy for N NCT06313450 | Sun Yat-sen University | N/A |
| Recruiting | Immunotherapy for Hepatocellular Carcinoma NCT06241326 | The First Affiliated Hospital with Nanjing Medical University | — |
| Recruiting | Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy NCT06276088 | Nanfang Hospital, Southern Medical University | — |
| Recruiting | Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy NCT06020430 | Hubei Cancer Hospital | N/A |
| Recruiting | Toripalimab Combined With Definitive CCRT for LACC Patients NCT06256224 | Ruijin Hospital | N/A |
| Recruiting | Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer NCT06215677 | Peking Union Medical College Hospital | N/A |
| Enrolling By Invitation | Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults NCT06777173 | Beijing Ditan Hospital | N/A |
| Unknown | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer NCT06134193 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Not Yet Recruiting | PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma NCT06125223 | Xijing Hospital | — |
| Recruiting | Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer NCT06093438 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 / Phase 2 |
| Completed | A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant NCT05848011 | MacroGenics | Phase 2 |
| Recruiting | Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Trea NCT06165900 | Shengjing Hospital | Phase 2 |
| Unknown | Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With Hi NCT06120127 | Fudan University | Phase 2 |
| Unknown | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery NCT06262581 | Sun Yat-sen University | Phase 2 |
| Unknown | Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Pro NCT06012318 | Guangdong Provincial People's Hospital | — |
| Completed | Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma NCT05304546 | Dr. Ronnie Shapira | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer NCT05479240 | Fujian Cancer Hospital | Phase 2 |
| Recruiting | Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC NCT06603402 | Sichuan University | Phase 2 |
| Recruiting | A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies NCT05862259 | Xinqiao Hospital of Chongqing | — |
| Active Not Recruiting | Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With NCT06128863 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 2 |
| Recruiting | Comparison Efficacy Between Two Different Frequency of Maintenance Dose Oral Immunotherapy NCT06035328 | Mahidol University | N/A |
| Recruiting | Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer NCT06014372 | Sun Yat-sen University | Phase 2 |
| Recruiting | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform NCT05520099 | Elephas | — |
| Recruiting | Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors NCT06302062 | Guangzhou FineImmune Biotechnology Co., LTD. | Phase 1 |
| Completed | The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Canc NCT06381895 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Completed | Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients W NCT05807893 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Unknown | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC NCT05982834 | Fudan University | Phase 1 / Phase 2 |
| Recruiting | The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study) NCT05967910 | Second Xiangya Hospital of Central South University | — |
| Unknown | Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers NCT05833672 | fan li | Phase 2 |
| Unknown | A Prospective Study to Observe Adverse Effects in Patients Receiving Anti-PD1 Immunotherapy NCT05669638 | Xuanwu Hospital, Beijing | — |
| Recruiting | Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients NCT05825443 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Unknown | Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection NCT05913583 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Completed | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Res NCT05775796 | Fudan University | Phase 2 |
| Recruiting | Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinom NCT06410651 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients NCT06429839 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA NCT06307249 | Lebanese University | Phase 1 |
| Recruiting | Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial NCT05652673 | Erasmus Medical Center | N/A |
| Recruiting | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcino NCT05613478 | The First Affiliated Hospital with Nanjing Medical University | Phase 3 |
| Completed | Estimating Lymphocyte Counts from DNA Methylation NCT06586307 | Sixth Affiliated Hospital, Sun Yat-sen University | — |
| Unknown | Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC NCT05901584 | Second Affiliated Hospital of Zunyi Medical University | Phase 2 |
| Unknown | Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cance NCT05935579 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC NCT06241807 | Shandong Cancer Hospital and Institute | Phase 2 |
| Recruiting | Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer NCT05354375 | The Affiliated Hospital of Xuzhou Medical University | Phase 1 |
| Unknown | Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients NCT05596890 | Guangdong Provincial People's Hospital | Phase 2 |
| Unknown | Clinical Study of the Safety and Efficacy of BCMA CAR-NK NCT05652530 | Shenzhen Pregene Biopharma Co., Ltd. | EARLY_Phase 1 |
| Active Not Recruiting | Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Canc NCT05621707 | Shanghai Chest Hospital | Phase 2 |
| Unknown | Trajectory Analysis of NLR and Its Association With Efficacy of Immunochemotherapy in ESCC. NCT06125262 | Guangdong Provincial People's Hospital | — |
| Unknown | Monitoring Allergen Immunotherapy in Allergic Rhinitis NCT05621356 | Rijnstate Hospital | — |
| Completed | A Phase I Study of GC101 TIL in Advanced Solid Tumors NCT05417750 | Shanghai Juncell Therapeutics | Phase 1 |
| Completed | Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas NCT05657262 | Kafkas University | N/A |
| Completed | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer NCT05215379 | Changhai Hospital | Phase 2 / Phase 3 |
| Completed | Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors NCT05515796 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Active Not Recruiting | Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy NCT04711330 | Leiden University Medical Center | — |
| Recruiting | Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung Cancer NCT06065813 | Northern Jiangsu People's Hospital | Phase 2 |
| Recruiting | A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB NCT05493267 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 4 |
| Recruiting | Longitudinal Neurocognitive, Psychosocial and Health-related Quality of Life Assessment in Advanced Cancer Sur NCT05667857 | Universitair Ziekenhuis Brussel | N/A |
| Unknown | Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy NCT06202781 | Chinese PLA General Hospital | — |
| Unknown | Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy NCT05817201 | Taizhou Hospital | Phase 2 / Phase 3 |
| Unknown | Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass NCT05487469 | Nanjing Medical University | N/A |
| Unknown | Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastri NCT05387681 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Unknown | TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in NCT05314101 | Fujian Cancer Hospital | Phase 2 |
| Unknown | SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positiv NCT05218148 | Aiping Zhou | Phase 2 |
| Unknown | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer NCT05311566 | Lei Li | Phase 2 |
| Unknown | Tislelizumab and Radiotherapy for Recurrent Cervical Cancer NCT05310383 | Lei Li | Phase 2 |
| Completed | Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium NCT05273827 | Tianjin Medical University Cancer Institute and Hospital | — |
| Completed | Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy NCT05273255 | Michael Scharl | N/A |
| Unknown | A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER- NCT05216237 | Jiuda Zhao | Phase 2 |
| Unknown | Checkpoint Inhibitors in Patients With Solid Tumors: a Retrospective Real-world Study NCT05719324 | The First Affiliated Hospital with Nanjing Medical University | — |
| Recruiting | Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer NCT06391190 | RenJi Hospital | Phase 1 / Phase 2 |
| Unknown | Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation NCT05460195 | Shanghai Chest Hospital | Phase 2 |
| Recruiting | the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer NCT06378840 | RenJi Hospital | — |
| Recruiting | Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic C NCT05202314 | Beijing Chao Yang Hospital | N/A |
| Unknown | Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM NCT05136768 | Jun-Lin Yi, MD | Phase 2 |
| Unknown | Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therap NCT04848454 | Peking University First Hospital | Phase 2 |
| Active Not Recruiting | Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. NCT05176002 | Fujian Medical University Union Hospital | Phase 1 / Phase 2 |
| Completed | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrm NCT05223088 | Fujian Cancer Hospital | Phase 2 |
| Unknown | Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer. NCT05025514 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC NCT06818097 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma NCT04969354 | The Affiliated Hospital of Xuzhou Medical University | Phase 1 |
| Terminated | Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer NCT05161572 | Fudan University | Phase 2 |
| Recruiting | Phase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Ad NCT05375734 | Second Affiliated Hospital of Nanchang University | Phase 2 |
| Unknown | Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Car NCT05024266 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Completed | Promoting INformed Approaches in Precision Oncology and ImmuNoTherapy NCT05034289 | Rutgers, The State University of New Jersey | N/A |
| Terminated | Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy NCT04037462 | VA Office of Research and Development | Phase 1 / Phase 2 |
| Recruiting | Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immun NCT05813418 | Centre Hospitalier Universitaire, Amiens | N/A |
| Recruiting | Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome NCT04999943 | Affiliated Hospital to Academy of Military Medical Sciences | Phase 1 |
| Not Yet Recruiting | An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy f NCT04890522 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Active Not Recruiting | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma NCT04387500 | West China Hospital | Phase 2 |
| Unknown | The Effect of Education and Telephone Follow-up Given to Cancer Patients Receiving Immunotherapy on Symptom Ma NCT05683652 | Ankara Medipol University | N/A |
| Recruiting | Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy NCT04957511 | Viome | — |
| Active Not Recruiting | Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment NCT04706598 | Fudan University | Phase 1 / Phase 2 |
| Unknown | Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations NCT04969029 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy. NCT04720339 | University Hospital, Strasbourg, France | N/A |
| Completed | mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC NCT04895137 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 |
| Unknown | PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AM NCT04722952 | The First Affiliated Hospital of Soochow University | Phase 3 |
| Active Not Recruiting | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinom NCT04521153 | Shanghai Zhongshan Hospital | Phase 2 / Phase 3 |
| Unknown | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer NCT04670445 | Massachusetts General Hospital | N/A |
| Unknown | Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma NCT05476965 | Hubei Cancer Hospital | Phase 2 |
| Unknown | Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Rese NCT04682210 | Sun Yat-sen University | Phase 3 |
| Unknown | Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer NCT04539600 | Sun Yat-sen University | Phase 2 |
| Completed | Checkpoint Inhibitors in Patients With Cancer and Underlying Autoimmune Disease NCT04805099 | Hellenic Cooperative Oncology Group | — |
| Unknown | Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors NCT04587817 | Peking University First Hospital | — |
| Completed | Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer NCT04821765 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Pro NCT04500990 | Peking University | — |
| Unknown | Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC NCT04372732 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Completed | Immunological Response After Shrimp Oral Immunotherapy Treatment NCT04552522 | Mahidol University | N/A |
| Recruiting | Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer NCT04688801 | The Second Hospital of Shandong University | N/A |
| Unknown | Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC NCT04547452 | West China Hospital | Phase 2 |
| Unknown | Immunotherapy in Lung Cancer: Treatment After IO Cessation. NCT04465942 | European Lung Cancer Working Party | — |
| Completed | Novel Dose Adjustment Schedule for Late Injection in SCIT in AR NCT04929093 | Beijing Tongren Hospital | Phase 4 |
| Completed | Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) NCT04271813 | Shanghai Changzheng Hospital | Phase 2 |
| Unknown | Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma. NCT04405622 | Sun Yat-sen University | Phase 2 |
| Completed | Clinical and Psycho-social Impact of COVID-19 Related Confinement on Patients With Digestive Tumors NCT04389684 | Poitiers University Hospital | — |
| Unknown | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma NCT04156698 | Eye & ENT Hospital of Fudan University | Phase 2 |
| Unknown | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failur NCT04586088 | Sun Yat-sen University | Phase 2 |
| Completed | The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients NCT04397575 | Federation Francophone de Cancerologie Digestive | — |
| Completed | Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients NCT04441424 | Alkarkh Health Directorate-Baghdad | N/A |
| Unknown | Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy NCT04641884 | Nantes University Hospital | — |
| Active Not Recruiting | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers NCT04169841 | Centre Georges Francois Leclerc | Phase 2 |
| Recruiting | Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) NCT04278222 | Shanghai Changzheng Hospital | Phase 2 |
| Recruiting | A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade NCT04807127 | Universitaire Ziekenhuizen KU Leuven | — |
| Recruiting | A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC NCT04807114 | Universitaire Ziekenhuizen KU Leuven | — |
| Withdrawn | Low-moderate Intensity Pedaling During Immunotherapy Administration NCT04127318 | Rush University Medical Center | N/A |
| Unknown | Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas NCT04570683 | Bispebjerg Hospital | EARLY_Phase 1 |
| Completed | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma NCT04225364 | Guangzhou Institute of Respiratory Disease | Phase 2 |
| Completed | Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy NCT04225390 | University of Erlangen-Nürnberg Medical School | Phase 2 |
| Unknown | Camrelizumab Combined With Local Treatment in NSCLC Patients With BM NCT04291092 | Zhejiang Cancer Hospital | Phase 2 |
| Unknown | COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer NCT03898895 | Sun Yat-sen University | Phase 2 |
| Completed | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy NCT04188860 | Lei Li | Phase 2 |
| Enrolling By Invitation | Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced NCT06849362 | Yue Gou | — |
| Active Not Recruiting | Omalizumab to Accelerate a Symptom-driven Multi-food OIT NCT04045301 | Philippe Bégin | Phase 2 |
| Unknown | Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer NCT04231552 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 / Phase 2 |
| Suspended | Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer NCT04558684 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 1 / Phase 2 |
| Completed | Patient Care Needs and the Decision-Making Experience of Patients With Cancer and Family Caregivers Regarding NCT05740800 | National Taiwan University Hospital | — |
| Completed | Cardiovascular Effects of CART Cell Therapy NCT04026737 | Abramson Cancer Center at Penn Medicine | — |
| Unknown | AImmune - Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict NCT04145232 | Ardigen | — |
| Unknown | PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer NCT03971214 | Chinese Academy of Medical Sciences | Phase 1 |
| Completed | Evaluation of Pain Alleviating Strategies During Allergy Shots NCT04181632 | Nemours Children's Clinic | N/A |
| Completed | Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSC NCT05637580 | Guangdong Provincial People's Hospital | — |
| Recruiting | The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China NCT04286841 | Guangdong Association of Clinical Trials | — |
| Unknown | Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma NCT04921995 | Fudan University | Phase 2 |
| Unknown | BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Dia NCT04136470 | Ardigen | — |
| Unknown | Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer NCT04110093 | Shanghai Changzheng Hospital | Phase 1 / Phase 2 |
| Unknown | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms NCT06065592 | Lebanese University | Phase 1 |
| Active Not Recruiting | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339 | Nanobiotix | Phase 1 |
| Completed | Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH) NCT05321212 | University Hospital, Brest | — |
| Recruiting | SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC NCT06889649 | Peking University First Hospital | Phase 2 |
| Completed | Study on the Applicability of CCR Criteria in Rectal Cancer NCT06794099 | Peking University Cancer Hospital & Institute | — |
| Unknown | Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer NCT03765190 | Peking University First Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Intra-Tumoral Vascular Growth Patterns is a Robust Indicator of Adjuvant Therapy Following Liver Resection in NCT06461936 | Chen Xiaoping | — |
| Unknown | An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal NCT05225844 | Harbin Medical University | Phase 2 |
| Unknown | Combination of Hypofractionated Proton Therapy With Immunotherapy NCT03764787 | Peking University First Hospital | Phase 1 / Phase 2 |
| Completed | Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan Populatio NCT03580070 | University Hospital Center of Martinique | — |
| Suspended | Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malig NCT03722186 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG NCT03695757 | Ajou University School of Medicine | Phase 1 / Phase 2 |
| Completed | Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Bi NCT05334849 | Lin Chen | — |
| Unknown | PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnor NCT03693326 | Asan Medical Center | Phase 2 |
| Unknown | Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liq NCT04993378 | Shen Lin | — |
| Unknown | Effect of Chemotherapy on TMB in NSCLC NCT03683407 | Baodong Qin | — |
| Unknown | Effect of Chemotherapy on PD-L1 in NSCLC NCT03701607 | Baodong Qin | — |
| Completed | Cancer Patients Treated With Immunotherapy in Intensive Care Unit NCT03357861 | University Hospital, Grenoble | — |
| Unknown | NK Cells Infusion for Advanced Malignancies NCT03619954 | Anhui Provincial Hospital | Phase 1 |
| Completed | The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Thera NCT04670107 | The Affiliated Hospital of Qingdao University | Phase 1 / Phase 2 |
| Recruiting | The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy NCT07260370 | Chang Gung Memorial Hospital | — |
| Completed | 18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy NCT03741231 | University Hospital, Brest | — |
| Unknown | Polish Microbiome Map NCT04169867 | Ardigen | — |
| Completed | MAPS & ITEC Cohorts: 6-8 Years Follow-up NCT03763630 | University of Southampton | Phase 2 |
| Unknown | RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial NCT03067493 | Sun Yat-sen University | Phase 2 |
| Recruiting | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression NCT03198546 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers NCT03198052 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Completed | ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurren NCT03003637 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Completed | Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced Malignancy NCT03042156 | University Health Network, Toronto | — |
| Unknown | Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy. NCT03563482 | Istituto Clinico Humanitas | N/A |
| Unknown | Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant NCT03066986 | Central Adelaide Local Health Network Incorporated | Phase 1 / Phase 2 |
| Completed | Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia. NCT04057703 | University Hospital, Bordeaux | — |
| Recruiting | Association of Psychological Distress in Patients With Lung Cancer NCT06218901 | Shanghai Chest Hospital | — |
| Completed | Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patie NCT02692976 | Radboud University Medical Center | Phase 2 |
| Completed | The Role of Tumor-associated Macrophages in Colorectal Liver Metastases NCT03888638 | Humanitas Clinical and Research Center | — |
| Recruiting | Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma NCT06571396 | Qilu Hospital of Shandong University | — |
| Unknown | Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions NCT02968394 | The University Clinic of Pulmonary and Allergic Diseases Golnik | N/A |
| Completed | Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects NCT03070561 | Johns Hopkins University | EARLY_Phase 1 |
| Completed | Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion NCT01256801 | Peking University Cancer Hospital & Institute | — |
| Completed | Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy NCT01475188 | Ministry of Science and Higher Education, Poland | Phase 4 |
| Completed | Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immun NCT00540150 | Johann Wolfgang Goethe University Hospital | Phase 3 |
| Recruiting | Neoadjuvant Treatment Modalities in Esophageal Cancer NCT04821843 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |
| Recruiting | Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer NCT04821778 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 |
| Completed | Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones NCT00720031 | Nantes University Hospital | Phase 1 / Phase 2 |